m+Medelevator.RU
← Поиск публикаций
Biotechnology progress · 2023

Impact of X-ray irradiation as an equivalent alternative to gamma for sterilization of single-use bioprocessing polymers.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Grzelak Adam W, Jeffkins Sarah, Luo Lan, Stilwell James, Hathcock James

Аннотация

Irradiation sterilization of polymeric pharmaceutical processing systems and medical devices, an essential healthcare technology, is facing critical business continuity challenges, driving the need to qualify equivalent alternative irradiation technologies, such as X-ray. Whereas the underlying there is a paucity of cross-industry published data evaluating X-ray irradiation effects on plastics as compared to gamma irradiation. That leads to regulatory uncertainty in the levels of costly validation data regulators will require and overall apprehension in the rate of X-ray irradiation adoption. The present study evaluates the impact of X-ray versus gamma irradiation on a wide range of polymers with more than 36 single-use (SU) components, using a comprehensive set of industry aligned methods for characterization of bioprocess polymers. Whereas many of these techniques readily demonstrate changes in polymer properties following irradiation, all of the polymers evaluated demonstrated that the impact of X-ray irradiation was to the same degree or less as compared to gamma. Increased publication of studies evaluating the impact to polymers of X-ray versus gamma irradiation is critical to leveraging extensive, existing validation packages on bioprocess systems and medical devices obtained following gamma irradiation, and essential in qualifying X-ray irradiation as an equivalent technology (i.e., materials are impacted to the same extent or less than gamma) that can overcome business continuity challenges to ensure continued availability of critical patient therapies.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты